KLRC1 and cancer: Furthermore, modulating this interaction might thus representa promising new therapeutic strategy for tackling various age-relateddiseases such as dementia, hypertension, atherosclerosis, cancer,autoimmune, and other diseases by the enhanced immune clearance ofsenescent cells.12 Checkpoint inhibitorsthat target NKG2A, such as the antibody monalizumab, are already inclinical trials as potential new anticancer drugs.13,14